KRAS and pancreatic intraductal papillary-mucinous neoplasm: In terms of the molecular profile of ITPN, the prevalence of alterations affecting the five classic PDAC/IPMN driver genes was as follows: KRAS mutated in 10.4% (5/48) of the patients, TP53 mutated in 4.7% (2/43) of the cases, CDKN2A was altered in 27.2% (6/22) of the cases, and SMAD4, GNAS, and RNF43 were altered in 0% of the cases.